Drugs / OPC1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06841770 | Jun 2025 → Aug 2027 expected | spinal cord injury | Lineage Cell Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2017-06-13 | Aivita Biomedical, Inc. | Results AIVITA Comments on Positive Findings from Asterias’ SCiStar Trial for Spinal Cord Injury aivitabiomedical.com ↗
AIVITA Biomedical offered its congratulations today following the announcement of positive 9-month efficacy and safety data from Asterias Biotherapeutics’ SCiStar Phase 1/2a clinical study for patients with complete cervical spinal cord injury (SCI). |
| 2007-11-13 | Geron Corporation | Results Journal of Neuroimmunology Publishes Study Results Showing that Geron´s Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System geron.com ↗
Geron Corporation (Nasdaq: GERN) today announced the publication of study results showing that GRNOPC1, the company’s human embryonic stem cell (hESC)–based therapeutic for the treatment of spinal cord injury, evades direct attack by the human immune system in vitro. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-06-13 | Aivita Biomedical, Inc. | AIVITA Comments on Positive Findings from Asterias’ SCiStar Trial for Spinal Cord Injury aivitabiomedical.com ↗ |
| 2007-11-13 | Geron Corporation | Journal of Neuroimmunology Publishes Study Results Showing that Geron´s Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System geron.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPC1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06841770 ↗ |